Ocupress

(Carteolol long-acting ophthalmic solution)

Phase 3Small molecule

AbbVie

Ocupress is one of 19 small molecule programs targeting Ocular Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Ocular HypertensionActive, not recruiting

Ocular HypertensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Alphagan

Novartis

Phase 3

1 2

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

9 3

Azopt

Novartis

Phase 3

1 4

LUMIGAN

AbbVie

Phase 3

2 5

Krytantek

AbbVie

Phase 3

2 6

Ocupress

AbbVie

Phase 3

1 7

Bimatoprost/timolol

AbbVie

Phase 3

4 8

Preservative-Free Tafluprost

Merck & Co.

Phase 3

2 9

Reference - LUMIGAN

AAmneal Pharmaceuticals, LLC

Phase 3

1 10

Duotrav

AAlcon Research

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ocular Hypertension1 trial

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Completed· Otsuka logo

Otsuka·Phase 3·NCT02105285·193 enrolled

Adult1 trial

Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers

Completed· Otsuka logo

Otsuka·Phase 1·NCT02108288·30 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 28, 1988

CARTROL

NDA NDA019204

May 23, 1990

OCUPRESS

NDA NDA019972

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Carteolol long-acting ophthalmic solution. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carteolol long-acting ophthalmic solution compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carteolol long-acting ophthalmic solution. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019972). U.S. Food & Drug Administration.
[5]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

Ocupress

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ocular Hypertension1 trial

Adult1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News